Abbreviation: SARS-CoV-2 variants EG
Policy Area: other (Health Emergency Response and Vaccines);Public Health
Lead DG: Health Emergency Preparedness and Response Authority
Mission: With a view to addressing the issue of the emerging and circulating SARS-CoV-2 variants for the purpose of development or adaptation of the EU COVID-19 vaccines, together with the related impact on the EU vaccines and therapeutics portfolio and strategy, the ‘Therapeutics Innovation Booster’ , and any action that the Commission may take in the matter, the Commission urgently needs to call upon the expertise of specialists. The expertise of the group shall cover epidemiology, virology, clinical practice, immunology, vaccinology, pharmacology, clinical assessment and medicinal product development and other relevant areas of expertise. The group tasks of the group shall be to establish criteria to identify SARS-CoV-2 variants of concern and variants of interest and to advise which variants should trigger adapted vaccine development for the Union and the EEA; to review the scientific evidence collected, to assist the Commission in gathering and interpreting the data needed to provide recommendations, etc.
Task: Assist the Commission in relation to the implementation of existing Union legislation, programmes and policies
Publication in RegExp: 22/07/2021
Creating Act: -
Last updated: 14/12/2022
Selection procedure: Members of the group shall be individuals appointed in their personal capacity (‘type A members’) as well as ECDC and EMA (‘type E members’)
Rules of procedure: COMMISSION DECISION of 24.6.2021 setting up the European group of experts on SARS-CoV-2 variants - C(2021) 4805 final The emergence and the spread of SARS-CoV-2 variants remains a threat to the health of the human population worldwide and the Union should have an operational system in place whereby the identification, assessment and characterisation of variants occurs in real time to allow for the swift adaptation of EU COVID-19 vaccines against the different variants of the SARS-CoV-2 virus, in the context of the negotiated Advance Purchase Agreements or new contracts to be set up.
C-2021-4805_EN_ACT_part1_v3.docx (approx. 71 kb)
No Subgroups assigned to this group.